
Varex Imaging (VREX) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
212.9M
Gross Profit
76.7M
36.03%
Operating Income
22.1M
10.38%
Net Income
7.1M
3.33%
EPS (Diluted)
$0.17
Balance Sheet Metrics
Total Assets
1.4B
Total Liabilities
793.7M
Shareholders Equity
563.9M
Debt to Equity
1.41
Cash Flow Metrics
Operating Cash Flow
11.6M
Free Cash Flow
9.8M
Revenue & Profitability Trend
Varex Imaging Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 811.0M | 893.4M | 859.4M | 818.1M | 738.3M |
Cost of Goods Sold | 554.1M | 603.1M | 575.9M | 546.6M | 548.1M |
Gross Profit | 256.9M | 290.3M | 283.5M | 271.5M | 190.2M |
Gross Margin % | 31.7% | 32.5% | 33.0% | 33.2% | 25.8% |
Operating Expenses | |||||
Research & Development | 87.0M | 84.8M | 77.0M | 71.9M | 78.9M |
Selling, General & Administrative | 137.8M | 128.4M | 118.3M | 125.5M | 142.2M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 224.8M | 213.2M | 195.3M | 197.4M | 221.1M |
Operating Income | 32.1M | 77.1M | 88.2M | 74.1M | -30.9M |
Operating Margin % | 4.0% | 8.6% | 10.3% | 9.1% | -4.2% |
Non-Operating Items | |||||
Interest Income | 7.3M | 3.7M | 400.0K | 100.0K | 100.0K |
Interest Expense | 26.8M | 26.7M | 36.4M | 38.6M | 24.4M |
Other Non-Operating Income | -4.2M | -20.2M | -4.3M | -3.5M | -10.4M |
Pre-tax Income | 5.0M | 31.3M | 44.5M | 28.6M | -72.6M |
Income Tax | 52.2M | -17.4M | 13.7M | 10.7M | -15.2M |
Effective Tax Rate % | 1,044.0% | -55.6% | 30.8% | 37.4% | 0.0% |
Net Income | -47.2M | 48.7M | 30.8M | 17.9M | -57.4M |
Net Margin % | -5.8% | 5.5% | 3.6% | 2.2% | -7.8% |
Key Metrics | |||||
EBITDA | 63.1M | 108.6M | 116.0M | 104.7M | -400.0K |
EPS (Basic) | $-1.17 | $1.20 | $0.76 | $0.44 | $-1.47 |
EPS (Diluted) | $-1.17 | $1.08 | $0.73 | $0.43 | $-1.47 |
Basic Shares Outstanding | 40800000 | 40300000 | 39800000 | 39300000 | 38800000 |
Diluted Shares Outstanding | 40800000 | 40300000 | 39800000 | 39300000 | 38800000 |
Income Statement Trend
Varex Imaging Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 168.7M | 152.6M | 89.4M | 144.6M | 100.6M |
Short-term Investments | 31.8M | 41.3M | - | - | - |
Accounts Receivable | 157.7M | 163.6M | 173.3M | 155.3M | 123.8M |
Inventory | 264.8M | 277.5M | 303.2M | 224.8M | 271.9M |
Other Current Assets | 26.9M | 23.3M | 44.0M | 29.5M | 25.7M |
Total Current Assets | 649.9M | 658.3M | 609.9M | 554.2M | 522.0M |
Non-Current Assets | |||||
Property, Plant & Equipment | 28.3M | 29.0M | 23.2M | 24.3M | 27.7M |
Goodwill | 598.1M | 599.4M | 602.6M | 635.1M | 653.7M |
Intangible Assets | 16.1M | 22.4M | 33.6M | 50.7M | 67.5M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 51.5M | 78.8M | 45.5M | 36.6M | 32.7M |
Total Non-Current Assets | 567.1M | 591.3M | 574.5M | 593.3M | 617.5M |
Total Assets | 1.2B | 1.2B | 1.2B | 1.1B | 1.1B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 59.1M | 64.7M | 78.2M | 58.8M | 72.9M |
Short-term Debt | 50.3M | 5.3M | 6.1M | 9.0M | 8.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 10.5M | 9.4M | 7.0M | 9.8M | - |
Total Current Liabilities | 195.9M | 162.8M | 173.1M | 166.6M | 160.6M |
Non-Current Liabilities | |||||
Long-term Debt | 420.1M | 464.2M | 430.3M | 450.4M | 475.9M |
Deferred Tax Liabilities | 1.4M | 0 | 500.0K | 2.2M | 2.3M |
Other Non-Current Liabilities | 31.9M | 26.9M | 26.2M | 24.1M | 24.5M |
Total Non-Current Liabilities | 471.9M | 505.8M | 464.6M | 484.4M | 513.1M |
Total Liabilities | 667.8M | 668.6M | 637.7M | 651.0M | 673.7M |
Equity | |||||
Common Stock | 400.0K | 400.0K | 400.0K | 400.0K | 400.0K |
Retained Earnings | 70.4M | 118.1M | 63.8M | 33.5M | 16.1M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 549.2M | 581.0M | 546.7M | 496.5M | 465.8M |
Key Metrics | |||||
Total Debt | 470.4M | 469.5M | 436.4M | 459.4M | 484.5M |
Working Capital | 454.0M | 495.5M | 436.8M | 387.6M | 361.4M |
Balance Sheet Composition
Varex Imaging Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -47.2M | 48.7M | 30.8M | 17.9M | -57.4M |
Depreciation & Amortization | 31.1M | 33.2M | 33.6M | 37.3M | 39.5M |
Stock-Based Compensation | 15.3M | 13.5M | 14.0M | 13.9M | 13.4M |
Working Capital Changes | 7.8M | 17.3M | -83.4M | -3.1M | -12.7M |
Operating Cash Flow | 48.3M | 78.8M | 12.5M | 74.3M | -10.5M |
Investing Activities | |||||
Capital Expenditures | -26.9M | -20.7M | -21.3M | -15.1M | -23.5M |
Acquisitions | 900.0K | -1.0M | 1.1M | -1.4M | -3.4M |
Investment Purchases | -61.0M | -55.9M | -28.3M | 0 | 0 |
Investment Sales | 60.6M | 35.3M | 2.0M | 0 | 0 |
Investing Cash Flow | -27.5M | -44.9M | -48.4M | -16.2M | -26.9M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | 0 | 0 | 1.5M | 593.8M |
Debt Repayment | -1.6M | -2.4M | -29.4M | -33.1M | -483.9M |
Financing Cash Flow | -7.1M | -4.3M | -32.5M | -35.1M | -455.2M |
Free Cash Flow | 20.4M | 87.7M | -4.4M | 77.5M | -10.3M |
Net Change in Cash | 13.7M | 29.6M | -68.4M | 23.0M | -492.6M |
Cash Flow Trend
Varex Imaging Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
19.08
Forward P/E
17.24
Price to Book
1.05
Price to Sales
0.58
PEG Ratio
0.00
Profitability Ratios
Profit Margin
-16.13%
Operating Margin
-39.75%
Return on Equity
-24.79%
Return on Assets
-1.96%
Financial Health
Current Ratio
3.51
Debt to Equity
84.54
Beta
0.68
Per Share Data
EPS (TTM)
$-3.23
Book Value per Share
$10.97
Revenue per Share
$19.91
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
vrex | 529.4M | 19.08 | 1.05 | -24.79% | -16.13% | 84.54 |
Abbott Laboratories | 243.2B | 16.64 | 4.57 | 30.93% | 32.43% | 26.50 |
Boston Scientific | 154.8B | 62.80 | 6.97 | 11.55% | 13.55% | 53.09 |
Enovis | 2.2B | -2.07 | 0.68 | -28.25% | -37.80% | 56.75 |
Conmed | 1.8B | 15.36 | 1.68 | 11.69% | 8.31% | 87.93 |
UFP Technologies | 1.7B | 24.38 | 4.20 | 19.29% | 11.40% | 46.98 |
Financial data is updated regularly. All figures are in the company's reporting currency.